| Glaucoma, Open-Angle
Lumigan vs Xalatan
Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.Deep comparison between: Lumigan vs Xalatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXalatan has a higher rate of injection site reactions vs Lumigan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalatan but not Lumigan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lumigan
Xalatan
At A Glance
Ophthalmic
Once daily
Prostaglandin analog
Ophthalmic
Once daily
Prostaglandin F2-alpha analogue
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle; Ocular Hypertension One drop in the affected eye(s) once daily in the evening; if used concomitantly with other topical ophthalmic drugs, administer at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily dosing.
Contraindications
- Hypersensitivity to bimatoprost or any excipient
- Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product
Adverse Reactions
Most common (>=1%) Conjunctival hyperemia, conjunctival edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, erythema of eyelid, eyelid pruritus, growth of eyelashes, hypertrichosis, instillation site irritation, punctate keratitis, skin hyperpigmentation, blurred vision, reduced visual acuity
Postmarketing Asthma-like symptoms, dizziness, dry eye, dyspnea, eye discharge, eye edema, foreign body sensation, headache, hypersensitivity, hypertension, increased lacrimation, periorbital and lid changes, photophobia
Most common (5-15%) Foreign body sensation, punctate keratitis, stinging, conjunctival hyperemia, blurred vision, itching, burning, increased pigmentation of the iris
Serious Iris pigmentation changes, eyelid skin darkening, eyelash changes, intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema
Postmarketing Dizziness, headache, toxic epidermal necrolysis, keratitis, corneal edema and erosions, trichiasis, iris cyst, conjunctivitis, pseudopemphigoid of the ocular conjunctiva, asthma, dyspnea, nausea, vomiting, pruritis, herpes keratitis, angina, palpitations, chest pain
Pharmacology
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes, selectively mimicking naturally occurring prostamides.
Latanoprost is a prostaglandin F2-alpha analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lumigan
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (9/12)
Xalatan
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Lumigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Xalatan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lumigan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Xalatan
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lumigan.
No savings programs available for Xalatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LumiganView full Lumigan profile
XalatanView full Xalatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.